A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Suzanne Leijen; Patricia M. M. B. Soetekouw; T. R. Jeffry Evans; Marianne Nicolson; Jan H. M. Schellens; Maria Learoyd; Lynda Grinsted; Victoria Zazulina; Thinn Pwint; Mark Middleton

doi:10.1007/s00280-011-1732-7

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Suzanne Leijen, Patricia M. M. B. Soetekouw, T. R. Jeffry Evans, Marianne Nicolson, Jan H. M. Schellens^*, Maria Learoyd, Lynda Grinsted, Victoria Zazulina, Thinn Pwint, Mark Middleton

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

32 Citations (Web of Science)

Original language	English
Pages (from-to)	1619-1628
Journal	Cancer Chemotherapy and Pharmacology
Volume	68
Issue number	6
DOIs	https://doi.org/10.1007/s00280-011-1732-7
Publication status	Published - Dec 2011

Keywords

MEK 1/2 inhibitor
Selumetinib
Phase I
Food effect

Access to Document

10.1007/s00280-011-1732-7

Cite this

Leijen, S., Soetekouw, P. M. M. B., Evans, T. R. J., Nicolson, M., Schellens, J. H. M., Learoyd, M., Grinsted, L., Zazulina, V., Pwint, T., & Middleton, M. (2011). A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 68(6), 1619-1628. https://doi.org/10.1007/s00280-011-1732-7

Leijen, Suzanne ; Soetekouw, Patricia M. M. B. ; Evans, T. R. Jeffry ; Nicolson, Marianne ; Schellens, Jan H. M. ; Learoyd, Maria ; Grinsted, Lynda ; Zazulina, Victoria ; Pwint, Thinn ; Middleton, Mark. / A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 68, No. 6. pp. 1619-1628.

@article{48ab5aeb3f9a4b89bd5ed9f3330dfe0f,

title = "A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors",

keywords = "MEK 1/2 inhibitor, Selumetinib, Phase I, Food effect",

author = "Suzanne Leijen and Soetekouw, {Patricia M. M. B.} and Evans, {T. R. Jeffry} and Marianne Nicolson and Schellens, {Jan H. M.} and Maria Learoyd and Lynda Grinsted and Victoria Zazulina and Thinn Pwint and Mark Middleton",

year = "2011",

month = dec,

doi = "10.1007/s00280-011-1732-7",

language = "English",

volume = "68",

pages = "1619--1628",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "6",

}

Leijen, S, Soetekouw, PMMB, Evans, TRJ, Nicolson, M, Schellens, JHM, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T & Middleton, M 2011, 'A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors', Cancer Chemotherapy and Pharmacology, vol. 68, no. 6, pp. 1619-1628. https://doi.org/10.1007/s00280-011-1732-7

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. / Leijen, Suzanne; Soetekouw, Patricia M. M. B.; Evans, T. R. Jeffry; Nicolson, Marianne; Schellens, Jan H. M.; Learoyd, Maria; Grinsted, Lynda; Zazulina, Victoria; Pwint, Thinn; Middleton, Mark.

In: Cancer Chemotherapy and Pharmacology, Vol. 68, No. 6, 12.2011, p. 1619-1628.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

AU - Leijen, Suzanne

AU - Soetekouw, Patricia M. M. B.

AU - Evans, T. R. Jeffry

AU - Nicolson, Marianne

AU - Schellens, Jan H. M.

AU - Learoyd, Maria

AU - Grinsted, Lynda

AU - Zazulina, Victoria

AU - Pwint, Thinn

AU - Middleton, Mark

PY - 2011/12

Y1 - 2011/12

KW - MEK 1/2 inhibitor

KW - Selumetinib

KW - Phase I

KW - Food effect

U2 - 10.1007/s00280-011-1732-7

DO - 10.1007/s00280-011-1732-7

M3 - Article

C2 - 21953275

VL - 68

SP - 1619

EP - 1628

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -

Leijen S, Soetekouw PMMB, Evans TRJ, Nicolson M, Schellens JHM, Learoyd M et al. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2011 Dec;68(6):1619-1628. https://doi.org/10.1007/s00280-011-1732-7